1. Discuss better the reason for the reported Uric acid cut-off. Your results seem in contrast to those published by Jung Tak Park et al (NDT 2009 ) in which authors, using a cut-off point of 7 mg/dl, did not find any difference in the rate of peritonitis between the two study groups.
2. Include in the statistical analysis at least hsPCR as marker of inflammation (this is mandatory in your paper).
3. Major Hypouricemic agents (for example, Allopurinol) should be included in the analysis separately.
4. Report and include in the analysis a more specific description of typologies and causes of peritonitis.
5. Add in the discussion more convincing pathophysiological reasons explaining the association among hypeuricemia and clinical outcomes.
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GENERAL COMMENTS
The study demonstrates that the high level of uric acid is a risk factor for all cause and peritonitis related technique failure in CAPD patients. The number of investigated patients (371) is moderate, but quite large for a CAPD study. The p values show the significant difference but they are not much lower than 0.05.
Major comments:
1) The authors did not report that they measured uric acid (UA) in drained dialysis fluid and urine. This is a drawback of the study because one cannot evaluate the removal of (UA) from the body and its generation rate. The plasma level of UA is the result of the balance between UA generation and removal. The lack of these data precludes the interpretation of the increased UA level in plasma: is it the result of increased generation or decreased removal? The application of equivalent continuous clearance of UA would allow for the comparison of the efficiency of UA removal among the patients and to other small solutes. These problems may be addressed in Discussion.
2) The number of patients at different time points of the follow-up should be presented.
3) Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population.). Other authors had used tertiles, quartiles or quintiles of uric acid levels to assess its effects on clinical outcomes. In order to increase the robustness of our findings, we performed the sensitivity analyses using the cutoff value of 7mg/dL and uric acid tertiles, which were added to the revised manuscript.
2. We did not have hsCRP in our data, but we had used ferritin as a marker of inflammation for the analysis.
3. The use of hypouricemic agent (allopurinol) had already recorded and included in the analysis, as shown in the "Patient and method" and table 1. The use of hypouricemic agent had been incorporated into the multivariate model. 4. We did not have detailed information on the typologies and causes of peritonitis in the current study. Since the main cause of technique failure was peritonitis, it might be also appropriate to include peritonitis rate in the analysis for our study. 5. Our retrospective study precluded us from clarifying the pathophysiologic mechanisms explaining the association between hyperuricemia and technique failure, which was mentioned as one of the major limitations in the Discussion. Although the proposed mechanisms are speculative without convincing evidence, the preliminary results of our study may provide a novel subject for further investigations.
Reviewer 2: 1. The serum uric acid level is the result of the balance between UA generation and removal. It may be important to determine whether hyperuricemia is attributed to the increased production or decreased removal. In the papers related to uric acid in the CKD patients (predialysis CKD, hemodialysis or peritoneal dialysis), most authors had used serum UA levels as the predictor without assessing the clearance of UA by the urine or dialysis. Furthermore, we did not have the data on the UA levels in the dialysis fluid and urine. It can be mentioned as one limitation if necessary. 2. The survival curves in the Kaplan-Meier plot provided the trend of the patient's cumulative survival for the two groups (normouricemia vs. hyperuricemia ). The mean follow-up duration was 36.69±27.53 months.
3. The first peritoneal equilibrium test (PET) and dialysis adequacy was done within one month of CAPD commencement. 4. The use of icodextrin or Balance dialysate was stable throughout the study period and included in the Cox regression models. 5. We added the median value±IQR for the patient age and follow-up duration. 6. The main aim of the current study was to evaluate the UA and technique failure. We did not assess the relation of UA to mortality. 7. A few minor spelling errors had been corrected.
